---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-030495"
form_type: "8-K"
ticker: "HEPA"
cik: "0001583771"
company_name: "Hepion Pharmaceuticals, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:45:21.151938+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Hepion Pharma's interim CEO/CFO resigns; executive chairman takes over

## Summary
- John Cavan departed as interim CEO and CFO on August 5, 2024 for personal reasons.
- John Brancaccio, executive chairman, appointed interim CEO and CFO effective August 6.
- Company is a clinical-stage biotech (HEPA) with no named permanent successor.

## SEC filing metadata
- accession: 0001493152-24-030495
- form_type: 8-K
- ticker: HEPA
- cik: 0001583771
- company_name: Hepion Pharmaceuticals, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583771/000149315224030495/0001493152-24-030495-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583771/000149315224030495/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-030495
- JSON: https://secwatch.observer/filing/0001493152-24-030495.json
- Plain text: https://secwatch.observer/filing/0001493152-24-030495.txt

## Key facts
- Executive change
  John Brancaccio was appointed as interim Chief Executive Officer and interim Chief Financial Officer at Hepion Pharmaceuticals, Inc..
  - Action: appointed
  - Role: interim Chief Executive Officer and interim Chief Financial Officer
  source text: On August 6, 2024, John Brancaccio, the Company’s executive chairman was appointed the interim Chief Executive Officer and interim Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000149315224030495/0001493152-24-030495-index.htm
- Executive change
  John Cavan departed as interim Chief Executive Officer and Chief Financial Officer at Hepion Pharmaceuticals, Inc..
  - Action: left
  - Role: interim Chief Executive Officer and Chief Financial Officer
  source text: On August 5, 2024, John Cavan, the interim Chief Executive Officer and Chief Financial Officer of Hepion Pharmaceuticals, Inc. (the “Company”) left the Company for personal reasons.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583771/000149315224030495/0001493152-24-030495-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.